cagrisema cagrilintide semaglutide phase 3 obesity Cagrilintide–semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, study In the REDEFINE 2 phase
Description
Discover the latest findings and what they mean for you

TRIUMPH trial updates and latest timeline.

Medical experts are concerned the full-body scans could do more harm than good setting up people who have no specific risk of cancer for overtreatment and overdiagnosis.

Immunofluorescence, Western blot, and RT-qPCR were used in the study

Dose increments are generally recommended every 4 weeks to minimize gastrointestinal side effects and improve compliance
